Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 0

Vitreomacular Traction andPharmacological Therapies

VitreomakülerTraksiyon veFarmakolojik Tedavisi

Pages
168–171
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Nowadays, in light of MİVİ-TRUST studies, intravitreal ocriplasmin therapy gains importance for the management of syptomatic VMT

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Vitreomacular traction (VMT) is a focal traction exerted by posterior vitreous on the macula.
📊
Key Findings & Data:Though spontaneous traction release may be possible, therapeutic intervention may be re- quired in cases with symptomatic VMT with or without macu- lar hole.
💡
Conclusion & Impact:Nowadays, in light of MİVİ-TRUST studies, intravitreal ocriplasmin therapy gains importance for the management of syptomatic VMT
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Vitreomacular traction (VMT) is a focal traction exerted by posterior vitreous on the macula. Though spontaneous traction release may be possible, therapeutic intervention may be re- quired in cases with symptomatic VMT with or without macu- lar hole. Pharmacological vitreolysis term is the induction of safe and uncomplicated detachment of posterior cortical vitre- ous from the macula with the help of biochemical substances by changing the nature of the vitreous. Nowadays, in light of MİVİ-TRUST studies, intravitreal ocriplasmin therapy gains importance for the management of syptomatic VMT

Özet

Vitreomaküler traksiyon (VMT), vitreusun fokal olarak makülada traksiyona yol açmasıdır. Her ne kadar spontan rezolusyon olasılığı varsa da, semptomatik ve/veya maküla deliği ile birlikte görülen olgularda müdahale gereksinimi doğabilmektedir.Farmakolojik vitreolizis terimi, vitreus yapısının kimyasal olarak değiştirilerek cerrahi girişime gerek kalmaksızın vitreusun maküladan emniyetli ve komplikasyonsuz ayrılmasıdır. MİVİ-TRUST çalışmaları ışığı altında VMT tedavisinde intravitreal okriplazmin tedavisi günümüzde önem kazanmaktadır

🔖

Cite This Article

SAATÇİ, A. O. (2015). Vitreomacular Traction andPharmacological Therapies. Retina-Vitreus, Cilt: 23 - Sayı: 0, 168–171. https://ajindex.com/articles/307892

References (15)

  1. Ponsioen TL, Hooymans JM, Los LI. Remodelling of the human vitre- ous and vitreoretinal interface-A dynamic process. Prog Retin Eye Res 2010;29:580-95. Bottós JM, Elizalde J, Rodrigues EB et al. Current concepts in vitreo- macular traction syndrome. Curr Opin Ophthalmol 2012;23:195-201.
  2. Reese AB, Jones IS, Cooper WC. Vitreomacular traction syndrome con- firmed histologically. Am J Ophthalmol 1970;69:975-7.
  3. Stalmans P, Duker JS, Kaiser PK et al. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina 2013;33:2003-11.
  4. Hikichi T, Yoshida A, Trempe CL. Course of vitreomacular traction syn- drome Am J Ophthalmol 1995;119:55-61.
  5. Odrobina D, Michalewska Z, Michalewski J et al. Long-term evaluation of vitreomacular traction disorder in spectral-domain optical coherence tomography Retina 2011;31:324-31.
  6. John VJ, Flynn HW Jr, Smiddy WE et al. Clinical course of vitreomacular adhesion managed by initial observation. Retina 2014;34:442-6.
  7. Yaman A, Karahan E, Arikan G, et al. Acute vitreomacular trac- tion syndrome after uneventful phacoemulsification. Ann Ophthalmol 2008;40:15-8.
  8. Duker JS, Kaiser PK, Binder S et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 2013;120:2611-9. Johnson MW. How should we release vitreomacular traction: surgically, pharmacologically, or pneumatically? Am J Ophthalmol 2013;155:203-5. Sebag J. Pharmacologic vitreolysis. Retina 1998;18:1-3.
  9. Wong SC, Capone A Jr. Microplasmin (ocriplasmin) in pediatric vitreo- retinal surgery: update and review. Retina 2013;33:339-48.
  10. Syed YY, Dhillon S. Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion. Drugs 2013;73:1617-25.
  11. Gandorfer A, Rohleder M, Sethi C et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004;45:641-7.
  12. Stalmans P, Benz MS, Gandorfer Aet al; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012;16:367:606-15.
  13. Saatci A.O, Kadayıfçılar S, Yaman A, ve ark. Vitreomaküler traksiyona bağlı evre 2 tam kat maküla deliğinde intravitreal okriplazmin tedavisi. Ret-Vit 2013:21:213-5.
  14. Kim BT, Schwartz SG, Smiddy WE et al. Initial outcomes following in- travitreal ocriplasmin for treatment of symptomatic vitreomacular adhe- sion. Ophthalmic Surg Lasers Imaging Retina 2013;44:334-43.
  15. Singh RP, Li A, Bedi R et al. Ana